PaibelIxia(Aguayao Hiraldo)Aguayo-HiraldoMDFAAP
Pediatric Hematology & Oncology • Los Angeles, CAPediatric Hematologic Oncology
Medical Director, Pediatric Bone Marrow Transplant and Cellular Therapy section
Dr. Aguayo-Hiraldo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4650 Sunset blvd
MS54
Los Angeles, CA 90027Phone+1 323-361-4755
Summary
- I am currently the medical director for the Transplant and Cellular Therapy section of the Cancer and Blood Disorders Institute at CHLA. My clinical interest includes stem cell transplants for non-malignant disorders, specifically immune deficiencies or disorders of immune dysregulation. My research focused on equitable access to cellular therapy and prevention/treatment of GVHD & TMA.
Education & Training
Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2013 - 2016
University of South Florida MorsaniResidency, Internal Medicine/Pediatrics, 2009 - 2013
San Juan Bautista School of MedicineClass of 2009, MD, Cum Laude
Certifications & Licensure
CA State Medical License 2018 - 2026
TX State Medical License 2016 - 2020
NM State Medical License 2013 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- COVID-19 vaccinated children, adolescents, and young adults with acute lymphoblastic leukemia show spike reactive antibodies and multifunctional T-cells.Rebecca S Parker, Justin Le, Miguel Villa, Annie Luong, Tsen Yin Lin
International Journal of Cancer. 2024-12-15 - Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT.Pietro Merli, Sonata Jodele, Eleanor Cook, Kasiani C Myers, Adam Lane
Bone Marrow Transplantation. 2024-12-03 - Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, Ingrid Vasova, Francis Ayuk
Transplantation and Cellular Therapy. 2024-11-26
Press Mentions
What Does It Mean to Be Immunocompromised?October 10th, 2024- 5 Reasons It’s Important for People of Color to Take Part in Clinical TrialsSeptember 30th, 2023
Professional Memberships
- Member
- Member
- Member
- American Society for Blood and marrow Transplantation-ASBMTMember
- American Society Pediatric Hematology and Oncology- ASPHOMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
